The drug to companies trying to invent new drugs to improve quality of life or cure diseases so we need to find balance between investment in resources against the CL options, public/private partnerships, as manufactures we invest and also want to sell. What I want to endorse is that drug access still has many more options available to increase drug access. Many PRIMA members and other partnerships are exploring new turfs. This system I want to see sustainable… a lot of times not included in negotiation and should be given more opportunity to increase drug access. There has been misunderstanding as to public/private consultation, and drug companies welcome the opportunities to work with other sectors.